Visus Therapeutics cashes in 20m from LSP
Visus Therapeutics has baged a 20m stock financing to advance development of Brimochol for presbyopia
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1190 entries already.
Entries by Thomas Gabrielczyk
British drug developer Mission Therapeutics plc earns $20m milestone
/in News/by Thomas GabrielczykBritish drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Spectricity raises 14m in Series B round
/in News/by Thomas GabrielczykBelgian semiconductor specialist Spectricity BV has baged 14m to speed up the development of mobile hyperspectral sensors for medical applications.
Abcam to acquire BioVision for $340m
/in News/by Thomas GabrielczykLife sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Byondis and Glycotope merge platforms to target carbohydrates
/in News/by Thomas GabrielczykCancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
/in News/by Thomas GabrielczykCancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
AXA IM Alts raises 1.9bn European Life Sciences Fund
/in News/by Thomas GabrielczykAXA IM Alts has raised 1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix inks $246m deal with ProfoundBio
/in News/by Thomas GabrielczykSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Stada und Calliditas Therapeutics in 97,5 Mio. Euro-Deal
/in News/by Thomas GabrielczykDie Stada Arzneimittel AG zahlt im Rahmen eines EU-Marketingabkommens für Nefecon zur Behandlung der IgA-Nephropathie vorab 20 Mio. Euro an die Calliditas Therapeutics AB.
Nanosyrinx raises £6.2m to validate drug delivery platform
/in News/by Thomas GabrielczykCoventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.